ReviewAmerican journal of clinical and experimental urology2015
Adenocarcinoma of the urinary bladder.
Review in American journal of clinical and experimental urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Genetic characteristics and targeted treatments of primary bladder and urachal adenocarcinomas: a systematic review with pooled descriptive genomic analyses.Cancer metastasis reviews · 2026Pooled it
- Clear cell urothelial carcinoma of the urinary bladder - a rare pathological entity. A case report and a systematic review of the literature.Bosnian journal of basic medical sciences · 2019Pooled it
- Malignancy yield and clinical predictors in radiologically detected adult urachal anomalies: A retrospective cohort study.BJUI compass · 2026Article
- Article
- Urinary bladder invasion secondary to dissemination of gallbladder cancer: an unusual presentation.Clinical journal of gastroenterology · 2026Article
- CK7-negative and CK20-Positive intestinal- type gastric adenocarcinoma metastasis to the bladder: A case report of an unprecedented phenotype.Urology case reports · 2025Article
- Article
- One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.Current treatment options in oncology · 2024Review
- Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.International journal of molecular sciences · 2023Review
- Bladder colloid carcinoma: A case report.Urology case reports · 2023Article
- Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.Cancer medicine · 2023Article
- Article
- A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study.European journal of medical research · 2023Article
- Article
- Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors.International journal of molecular sciences · 2022Review
- Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation.Frontiers in oncology · 2022Article
- Clinicopathological Characteristics and Prognostic Factors of Primary Bladder Signet Ring Cell Carcinoma.Journal of healthcare engineering · 2022Article
- Semantic Segmentation of Urinary Bladder Cancer Masses from CT Images: A Transfer Learning Approach.Biology · 2021Article
- An unusual presentation of synchronous bladder metastases from an oesophageal adenocarcinoma.Annals of the Royal College of Surgeons of England · 2021Article
- Metastasis of Duodenal Adenocarcinoma to the Urinary Bladder Presenting as Hematuria.Journal of translational internal medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Adenocarcinoma is an uncommon malignancy in the urinary bladder which may arise primarily in the bladder as well as secondarily from a number of other organs. Our aim is to provide updated information on primary and secondary bladder adenocarcinomas, with focus on pathologic features, differential diagnosis, and clinical relevance. Primary bladder adenocarcinoma exhibits several different growth patterns, including enteric, mucinous, signet-ring cell, not otherwise specified, and mixed patterns. Urachal adenocarcinoma demonstrates similar histologic features but it can be distinguished from bladder adenocarcinoma on careful pathologic examination. Secondary bladder adenocarcinomas may arise from the colorectum, prostate, endometrium, cervix and other sites. Immunohistochemical study is valuable in identifying the origin of secondary adenocarcinomas. Noninvasive neoplastic glandular lesions, adenocarcinoma in situ and villous adenoma, are frequently associated with bladder adenocarcinoma. It is also important to differentiate bladder adenocarcinoma from a number of nonneoplastic lesions in the bladder. Primary bladder adenocarcinoma has a poor prognosis largely because it is usually diagnosed at an advanced stage. Urachal adenocarcinoma shares similar histologic features with bladder adenocarcinoma, but it has a more favorable prognosis than bladder adenocarcinoma, partly due to the relative young age of patients with urachal adenocarcinoma.
Indexed as
Identifiers
26309895PMC4539107W2404135977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.